Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen.

Christina Peters, Angela Bruno, Carmelo Rizzari, Alessandra Brescianini, Arend Von Stackelberg, Christin Linderkamp, Yi Zeng, Gerhard Zugmaier, Franco Locatelli

Haematologica 2024 September 5

Not available.

Full text links

We have located open access text paper links.

Full Text PDF

Show additional links to paperHide additional links to paper

PubMed Haematologica

Add to Saved Papers

Get 1-tap access

Related Resources

How to Approach Patients with Acute Chest Pain.Kenji Inoue, Tohru MinaminoReviews in Cardiovascular Medicine 2024 August

Novel Insights into Diabetic Kidney Disease.Ewelina Młynarska et al.International Journal of Molecular Sciences 2024 September 23

Central venous catheter insertion site and infection prevention in 2024.Harm-Jan de Grooth, Stefan Hagel, Olivier MimozIntensive Care Medicine 2024 September 30

For the best experience, use the Read mobile app

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Blinatumomab is associated with better post-transplant outcome than chemotherapy in children with high-risk first-relapse B-cell acute lymphoblastic leukemia irrespective of the conditioning regimen.

Full text links

Related Resources

Trending Papers

For the best experience, use the Read mobile app